Health

STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 21:51:25 UTC.

Briefing in preparation

The French pharma Servier said Tuesday that an experimental drug it purchased in June for $1.55 billion in cash, plus about $1 billion more in potential milestones, failed to slow a rare form of muscular dystrophy in a long placebo-controlled trial. It’s a surprising setback for both Servier and the patients with Becker muscular dystrophy, who currently have no approved treatments. The drug, called sevasemten and originally developed by Edgewise Therapeutics, had previously shown promising results in a smaller, randomized study. “The results of the pivotal GRAND CANYON study are not aligned wi

An expanded briefing is queued. The original source is available above.

IPFS archive pending.